Generate a tailored SOP for Dr. Imran Khan. Improve your application with a focused, well-structured draft.
Imran H. Khan is an adjunct professor at the University of California, Davis, in the Department of Pathology and Laboratory Medicine. His research interests focus on studying biomarkers and intracellular signaling pathways, particularly related to cancer and infectious diseases. He has developed highly efficient, high-throughput multiplex approaches for studying proteomic genetic biomarkers and has worked on simultaneous analysis of multiple key components of cell signaling pathways in a single reaction vessel. Dr. Khan employs novel methods to investigate disease-related biomarkers in bodily fluids, including plasma, serum, and dried blood spots, leveraging the power of multiplexing systems and computational modeling. His results have been published in peer-reviewed journals. Dr. Khan earned his Ph.D. from the Albert Einstein College of Medicine, where his thesis research focused on elucidating the molecular mechanisms of bacterial intracellular signaling. He completed postdoctoral research at UC Davis, studying the molecular pathogenesis of AIDS and intracellular signaling in SIV-infected T cells using a rhesus macaque model. Dr. Khan has also worked in the industry, contributing to the development of retroviral vaccines at Intervet-Akzo Nobel Company and conducting research at Onyx Pharmaceuticals, focusing on intracellular signaling to define novel drug targets for cancer therapeutics. He returned to UC Davis in 2001, continuing his academic career.
University of California, Davis • Sacramento, CA
Teaches and leads research in the Department of Pathology and Laboratory Medicine.
University of California, Davis • Sacramento, CA
Oversees operations of the Proteomics Core Lab.
Onyx Pharmaceuticals • CA
Focused research on intracellular signaling to define novel drug targets for cancer therapeutics.
University of California, Davis • Sacramento, CA
Studied molecular pathogenesis of AIDS and intracellular signaling in SIV-infected T cells.
Intervet-Akzo Nobel Company • NY
Worked on development of retroviral vaccines.
Department of Computer Science. GRE is NOT required.